- Home
- XOMA vs AQST Comparison
XOMA vs AQST Comparison
Compare XOMA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- AQST
- Stock Information
- Founded
- XOMA 1981
- AQST 2004
- Country
- XOMA United States
- AQST United States
- Employees
- XOMA N/A
- AQST N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- XOMA Health Care
- AQST Health Care
- Exchange
- XOMA Nasdaq
- AQST Nasdaq
- Market Cap
- XOMA 457.6M
- AQST 390.4M
- IPO Year
- XOMA N/A
- AQST 2018
- Fundamental
- Price
- XOMA $39.01
- AQST $5.88
- Analyst Decision
- XOMA Strong Buy
- AQST Strong Buy
- Analyst Count
- XOMA 2
- AQST 7
- Target Price
- XOMA $69.50
- AQST $10.29
- AVG Volume (30 Days)
- XOMA 55.5K
- AQST 3.6M
- Earning Date
- XOMA 11-06-2025
- AQST 11-03-2025
- Dividend Yield
- XOMA N/A
- AQST N/A
- EPS Growth
- XOMA N/A
- AQST N/A
- EPS
- XOMA N/A
- AQST N/A
- Revenue
- XOMA $44,952,000.00
- AQST $44,132,000.00
- Revenue This Year
- XOMA $88.91
- AQST N/A
- Revenue Next Year
- XOMA $13.80
- AQST $51.50
- P/E Ratio
- XOMA N/A
- AQST N/A
- Revenue Growth
- XOMA 194.98
- AQST N/A
- 52 Week Low
- XOMA $18.35
- AQST $2.12
- 52 Week High
- XOMA $39.92
- AQST $6.43
- Technical
- Relative Strength Index (RSI)
- XOMA 66.59
- AQST 62.35
- Support Level
- XOMA $34.42
- AQST $5.47
- Resistance Level
- XOMA $39.92
- AQST $5.93
- Average True Range (ATR)
- XOMA 1.88
- AQST 0.35
- MACD
- XOMA 0.01
- AQST 0.01
- Stochastic Oscillator
- XOMA 90.81
- AQST 62.73
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.